Metformin and the Longevity Debate That Won't Resolve

Metformin has been used to manage type 2 diabetes for decades, working primarily by reducing glucose production in the liver and improving insulin sensitivity. Interest in metformin's relevance to aging grew after observational studies found that diabetic patients taking metformin sometimes had lower mortality rates than non-diabetic people not taking the drug at all, an unusual and widely discussed finding.

The proposed mechanisms connecting metformin to aging biology include effects on AMPK activation, reduced oxidative stress, and changes in the gut microbiome, several of which overlap with pathways implicated in caloric restriction research. A large trial called TAME, Targeting Aging with Metformin, was designed specifically to test whether metformin delays the onset of multiple age-related diseases in non-diabetics, though funding and regulatory hurdles around treating aging itself as a trial endpoint have repeatedly slowed its progress.

Why this matters for tracking: metformin sits in an unusual position of having decades of human safety data as a diabetes drug while its specific anti-aging effects in non-diabetics remain formally unproven, which is exactly what the TAME trial was designed to resolve.